Results 171 to 180 of about 64,235 (269)

An App‐Based Proton Pump Inhibitor Discontinuation Tool: A Multicentre, Open‐Label, Randomised Superiority Trial

United European Gastroenterology Journal, Volume 14, Issue 8, October 2026.
ABSTRACT Background Proton pump inhibitors (PPIs) are frequently used without long‐term indication. Discontinuation remains challenging because of rebound symptoms. Whether digital guidance tools improve discontinuation is unknown. We evaluated whether an app improves PPI discontinuation.
Lieke M. Koggel, Thomas Timmers, Marten A. Lantinga, Rudolf B. Kool, Cornelis Kramers, Noortje van Herwaarden, Peter D. Siersema, on behalf of the SUPPORT study consortium, B. A. J. Veldman, A. C. I. T. L. Tan, L. B. Hilbrands, I. L. Meek   +11 more
wiley   +1 more source

The genetic association between celiac disease and risk of functional dyspepsia: A Mendelian randomization study. [PDF]

Medicine (Baltimore)
Tang J, Zhao R, Yuan Z, Li J, Cui X.
europepmc   +1 more source

Rome V Criteria for Adults: What's New and Why?

United European Gastroenterology Journal, Volume 14, Issue 8, October 2026.
ABSTRACT The Rome V criteria, published in 2026, represent the culmination of a 7‐year effort to refine and improve the diagnostic framework for disorders of gut–brain interaction. The revision incorporates the latest consensus guidelines and emerging research while moving away from stigmatizing language and toward a more personalized, patient‐centered
Amanda Krause, Lin Chang
wiley   +1 more source

Symptom Profiles Compatible With Disorders of Gut‐Brain Interaction in Individuals With Coeliac Disease on a Long‐Term Gluten‐Free Diet

United European Gastroenterology Journal, Volume 14, Issue 8, October 2026.
ABSTRACT Background Persistent gastrointestinal (GI) symptoms are frequently reported in patients with coeliac disease (CD). Knowledge about the role of disorders of gut‐brain interaction (DGBI) as the cause of these persistent symptoms remains limited.
Tom van Gils, Hans Törnblom, Floris van Overveld, Olafur S. Palsson, Ami D. Sperber, Shrikant I. Bangdiwala, Inês A. Trindade, Marc A. Benninga, Gerd Bouma, Magnus Simrén   +9 more
wiley   +1 more source

The Role of Diet in Functional Dyspepsia. [PDF]

Nutrients
Bertin L, Van de Bruaene C, Formisano E, Pesce M, Piccirelli S, Salvi D, Routhiaux K, Pasta A, Calabrese F, Caldart F, Crucillà S, Sarnelli G, Marabotto E, Chahuan J, van Gils T, Savarino EV.   +15 more
europepmc   +1 more source

Minimal residual disease–guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype

British Journal of Haematology, Volume 209, Issue 4, Page 1664-1672, October 2026.
Minimal residual disease (MRD)–guided ibrutinib and venetoclax (IVen) achieved durable remissions and high undetectable MRD (uMRD) rates in patients with high‐risk chronic lymphocytic leukaemia (CLL). Compared with historical ibrutinib monotherapy, IVen was associated with improved progression‐free and overall survival despite presence of complex ...
Maria Kislova, Elena Dmitrieva, Elena Naumova, Margarita Pochtar, Svetlana Lugovskaya, Yury Kobzev, Alla Loban, Maria Gladysheva, Tatiana Obukhova, Bella Biderman, Andrey Sudarikov, Egor Volchkov, Maria Ivanova, Vadim Ptushkin, Andrea Visentin, Eugene Nikitin   +15 more
wiley   +1 more source

Sex-Specific Differences in Dyspeptic Symptoms in Children Are Attenuated by <i>Helicobacter pylori</i> Seropositivity. [PDF]

Pediatr Gastroenterol Hepatol Nutr
Ilic D, Jovanovic N, Bjelakovic B.
europepmc   +1 more source

Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta‐Analysis of Head‐to‐Head Studies

Clinical Obesity, Volume 16, Issue 5, October 2026.
ABSTRACT This systematic review and meta‐analysis aimed to compare the efficacy and safety of tirzepatide versus semaglutide for weight reduction in adults with overweight or obesity. We included randomised controlled trials and observational studies comparing tirzepatide and semaglutide with ≥ 24 weeks of follow‐up.
Giovanna Pagani Paccola, Roberta Fernandes de Oliveira, Matheus Menão Mochetti, Fernanda Pataro Marsola Razera, Rafael Vecchi, Renan Canale Peres Montanher   +5 more
wiley   +1 more source

Beyond the Snapshot: Overcoming GES Limitations to Characterize Gastric Phenotypes and Therapeutic Responses Using a 6-Day Ambulatory Wearable Monitor. [PDF]

Neurogastroenterol Motil
Lacy BE, Cangemi DJ, Axelrod L, Axelrod S, Navalgund A.   +4 more
europepmc   +1 more source

Real‐World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9621-9632, October 2026.
ABSTRACT Background Tirzepatide has demonstrated substantial weight‐loss efficacy in clinical trials, but real‐world evidence from routine digital prescribing remains limited. Methods We conducted a retrospective cohort study of adults initiating tirzepatide for obesity via a UK digital prescribing service between March 2024 and July 2025. Linked order‐
Onayomi Rosenior‐Patten, Zoe Lees, Rebecca Rowe, Safia Hussain, Ehtasham Ahmad, Edward Brooke, Sophie Dix, Catriona Maybury   +7 more
wiley   +1 more source